Latest News - Bristol-Myers Squibb
Top Corporates Hub
Bristol-Myers Squibb
Tempus AI, Inc. (TEM) and Bristol Myers Announce a Strategic Partnership
23.05.2026 04:49
Tempus AI, Inc. (NASDAQ:TEM) is one of the 10 Best ARK Stocks to Buy Right Now. On May 14, Tempus AI, Inc. (NASDAQ:TEM) announced a collaboration with Bristol Myers Squibb to maximize clinical trials. The partnership will use multimodal data and AI to improve trial design and boost the probability of technical and regulatory success […]
Vanguard’s VIG Quietly Returned 247% While Investors Chased Higher Yields
22.05.2026 16:14
Retirees evaluating dividend funds tend to anchor on current yield, which is exactly why Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) often gets overlooked. The fund pays a distribution yield of roughly 1.6%, which looks unimpressive next to higher-yielding alternatives. Morningstar analysts have repeatedly flagged VIG as a quiet winner for retirees precisely because of that misread. ... Vanguard’s VIG Quietly Returned 247% While Investors Chased Higher Yields
1 Profitable Stock to Keep an Eye On and 2 We Brush Off
22.05.2026 16:04
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
22.05.2026 12:03
Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory pain data may point to additional clinical opportunities for the LPA1 receptor antagonist. Sp
Bristol Myers Bets On Claude AI And Neuroscience To Recast Growth
22.05.2026 04:32
Bristol Myers Squibb (NYSE:BMY) is rolling out Anthropic's Claude enterprise AI across its global operations. The company is broadening its neuroscience focus after a US$14b acquisition, adding drug candidates for schizophrenia and Alzheimer's disease. These moves reflect a shift toward large scale AI use in pharma and a wider footprint beyond oncology. Bristol Myers Squibb is a large pharmaceutical company best known for its work in oncology and immunology. A full scale deployment of...
BMS and Anthropic collaborate for Claude implementation
21.05.2026 10:18
BMS will roll out Claude to over 30,000 employees, targeting three main areas for near-term impact.
In Alzheimer’s, Bristol Myers sees big promise beyond amyloid
21.05.2026 09:00
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
BioArctic AB (BRCTF) Q1 2026 Earnings Call Highlights: Strong Sales and Strategic Partnerships ...
20.05.2026 15:01
BioArctic AB (BRCTF) reports robust financial performance and advances in Alzheimer's treatment, while navigating market access hurdles and rising operational costs.
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery
20.05.2026 13:09
Bristol Myers Squibb expands AI efforts through Anthropic and Tempus partnerships as shares edge higher Wednesday.
Bristol Myers deepens AI investment with Anthropic deal
20.05.2026 11:28
The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-day activities.
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
20.05.2026 10:59
PRINCETON, N.J., May 20, 2026--Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across...
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout
19.05.2026 13:33
Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including...
A Look At Bristol Myers Squibb (BMY) Valuation After Major Hengrui Collaboration Announcement
15.05.2026 09:15
Bristol-Myers Squibb (BMY) has just signed a collaboration and licensing agreement with Hengrui Pharma covering 13 early stage oncology, hematology and immunology programs, a large commitment that could reshape its future pipeline. See our latest analysis for Bristol-Myers Squibb. At a share price of $56.77, Bristol-Myers Squibb has a 1-year total shareholder return of 30.12%, while the year to date share price return of 6.19% and recent 90 day share price weakness suggest momentum has...
Employers Gain As Second Circuit Restricts Out-of-State Plaintiffs From Joining FLSA Collective Actions
15.05.2026 06:11
Takeaways ...
Bristol-Myers Squibb Company (BMY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
14.05.2026 14:40
Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2026 May 14, 2026 11:40 AM EDTCompany ParticipantsAdam Lenkowsky - Executive...
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts
14.05.2026 14:23
Tempus AI And Bristol Myers Squibb Expand AI-Driven Trial Design Efforts Across Oncology And Alzheimer's Programs
Transcript : Bristol-Myers Squibb Company Presents at Bank of America Global Healthcare Conference 2026, May-14-2026 08
14.05.2026 13:05
Presenter SpeechJason Gerberry All right, everybody. We're going to get going here with our next company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I cover
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
14.05.2026 12:30
CHICAGO, May 14, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs.
Tempus AI Partners With Bristol Myers Squibb Over Leveraging AI, Multimodal Real-World Data, Data Science Techniques For Clinical Trial Designs
14.05.2026 08:40
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to leverage AI,
Bristol-Myers Strikes $15.2 Billion China Drug Deal
13.05.2026 12:57
Bristol-Myers will pay Hengrui up to $950 million by 2028 for 13 early-stage programs.